Crescent Biopharma, Inc. Share Price

Crescent Biopharma, Inc. Share Price

NASDAQ: CBIO
$14.77
+$1.25 (9.29%) Last updated on 29 Oct, 2026 | 21:00 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Crescent Biopharma, Inc. Stock Performance

Open
$13.57
Prev. Close
$13.52
Circuit Range
N/A
Day Range
$13.57 - $14.78
Year Range
$8.81 - $27.41
Volume
7,297
Average Traded
$14.31

Crescent Biopharma, Inc. Share Price Today

As of 29 October 2026, Crescent Biopharma, Inc.'s share price is $14.77. The stock opened at $13.57, compared to its previous close of $13.52. During today's trading session, Crescent Biopharma, Inc.'s share price traded between $13.57 and $14.78, with an average price of $14.18. Over the past 52 weeks, the stock has recorded a high of $27.41 and a low of $8.81. In terms of performance, Crescent Biopharma, Inc.'s share price has declined by 33.78% over the last six months and is up 16.07% on a year-on-year basis.

Crescent Biopharma, Inc. Share Price Chart

Line chart of the Crescent Biopharma, Inc. price trend over the selected period. The price rose overall, ranging from 13.57 to 14.79, ending at 14.77.
$13.57$14.78
L
Show Current Price
H

Crescent Biopharma, Inc. Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-3.93
Revenue (TTM)
$10.84B
Return On Equity (TTM)
-89.40%
Profit Margin
-1231.09%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-8.31%

Crescent Biopharma, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$10.84$1.04$0.00
Net Profit-$20.95-$81.06-$21.26-$22.69
Net Profit MarginN/A-747.79%-2044.23%N/A
Income ChangeN/A-286.92%73.77%-6.73%

Crescent Biopharma, Inc. Annual Profit & Loss

All figures in USD

Particulars20222025
Revenue$102.29$10.84
Net Profit$2.30-$133.45
Net Profit Margin2.25%-1231.09%
Income ChangeN/A-5902.17%

About Crescent Biopharma, Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Crescent Biopharma, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$14.48
$14.38
-2.54%
Sep 2026
$16.50
$14.76
-18.66%
Aug 2026
$14.59
$18.14
+25.62%
Jul 2026
$17.91
$14.44
-19.62%
Jun 2026
$19.60
$17.96
-12.60%
May 2026
$20.53
$20.55
-7.85%
Apr 2026
$18.83
$22.30
+21.32%
Mar 2026
$11.75
$18.39
+51.19%
Feb 2026
$9.89
$12.16
+27.20%
Jan 2026
$11.51
$9.56
-19.05%
Dec 2025
$14.57
$11.81
-22.51%
Nov 2025
$12.51
$15.24
+19.76%

CBIO Share Price FAQs